Yes, but $57m of the NPAT $$188m is a non-cash item. It is a revaluation "net gain on step acquisition of associate" as per note 21.
What else looks odd in the FY18 accounts?
For starters, although revenue is up 19%, cash flow from operating activities is down from $125m to $119m. Not a good look and the reason is not apparent.
Then there is the increase in debt - up $262m to fund the increase in ownership of associated company. Gearing has shot up to 135% using my measurement (debt/equity).
Worse, total intangibles jumped to $658m compared with equity at year end of only $335m.
Seems to me that CAR badly needs a discounted share issue. However the market disagrees, as the price increased 10%.
- Forums
- ASX - By Stock
- Ann: FY18 Results Presentation
Yes, but $57m of the NPAT $$188m is a non-cash item. It is a...
Featured News
Add CAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$33.68 |
Change
-0.690(2.01%) |
Mkt cap ! $12.79B |
Open | High | Low | Value | Volume |
$34.28 | $34.39 | $33.65 | $15.84M | 467.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 6408 | $37.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$30.49 | 4167 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 3863 | 37.040 |
1 | 40000 | 35.400 |
19 | 18810 | 35.370 |
27 | 61497 | 35.360 |
1 | 317 | 35.190 |
Price($) | Vol. | No. |
---|---|---|
30.490 | 4167 | 1 |
30.540 | 3100 | 1 |
31.040 | 1259 | 2 |
31.160 | 6944 | 1 |
31.330 | 12675 | 2 |
Last trade - 15.59pm 03/07/2024 (20 minute delay) ? |
Featured News
CAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online